公开(公告)号：EP3233920A4

公开(公告)日：2018-07-25

申请号：EP15871152

申请日：2015-12-18

申请人： ALKERMES INC

发明人： ALVARAZ JUAN ,  MOUSTAKAS DEMETRI T ,  BRODKIN HEATHER R ,  MCSWEENEY LESLIE A

IPC分类号： C07K16/30

CPC分类号： A61K47/48369 ,  A61K38/00 ,  A61K38/179 ,  A61K38/1793 ,  A61K38/2013 ,  A61K38/2066 ,  A61K38/215 ,  A61K38/4846 ,  C07K14/5428 ,  C07K14/55 ,  C07K14/565 ,  C07K14/70578 ,  C07K14/7151 ,  C07K14/7155 ,  C07K2319/30 ,  C07K2319/70 ,  C12N9/644 ,  C12Y304/21022

摘要： The present invention provides novel, single chain Fc fusion proteins having improved properties. The invention provides single chain fusions of soluble proteins fused to the Fc region of an immunoglobulin via a novel linker comprising a constant region of an immunoglobulin light chain linked to a CH1 constant region of an immunoglobulin heavy chain. This novel linker confers favorable properties on the Fc fusion proteins of the invention such as improved bioactivity and increased half-life as compared to non-Fc fusion counterparts or as compared to prior art Fc fusion proteins. The novel Fc fusion protein scaffold as described herein may be designed to include soluble proteins of interest capable of binding or interacting with any target of interest. Preferably, the Fc fusion protein of the invention is a dimer. The dimer preferably forms via a disulfide bond between free cysteine residues in the hinge region of two monomeric Fc fusion proteins of the invention.

公开(公告)号：EP2858672A4

公开(公告)日：2016-02-10

申请号：EP13800676

申请日：2013-06-06

申请人： ALKERMES INC

发明人： ALVAREZ JUAN ,  MCSWEENEY LESLIE A

IPC分类号： C12N15/62 ,  C07K14/47

CPC分类号： C07K14/55 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/4713 ,  C07K14/4727 ,  C07K14/50 ,  C07K14/54 ,  C07K14/5412 ,  C07K14/5443 ,  C07K14/545 ,  C07K14/57563 ,  C07K14/70503 ,  C07K14/71 ,  C07K14/7155 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/74 ,  C07K2319/91

摘要： The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof.